|
|
|
Choosing Axxam for your high-throughput screening needs is about more than just receiving a list of "hits". It’s about variable library capacity, tight coupling with our assay development scientists, both cell-based and biochemical assays, using luminescent and fluorescent detection - and using the latest instrumentation to generate high-quality analytical reports.
We can conduct high-throughput screening by using either Axxam’s
Compound Collections or your libraries that you supply to us. Axxam is equipped to handle your libraries in 384-MTP and, of course, your libraries will be handled securely and with the greatest confidentiality. Naturally any intellectual property generated with the compounds belongs to the customer.
We can screen almost any target relevant to the pharmaceutical industry, including GPCRs, nuclear hormone receptors, ion channels, and enzymes. You benefit from the tight coupling between assay development and screening at Axxam. First, assays can move seamlessly from assay development into HTS with minimal delay if you also partner with Axxam for assay development. Second, optimal performance of the screening campaign is ensured with scientists from both groups committed to the success of the complete project.
The flexible screening facility we have created can adapt to the demands of multiple assay formats. Our main screening platform is built around a CyBio® screening system for 384-MTPs. For luminescent assays we employ either a CyBio® Lumax HTS - a highly-sensitive luminescent plate reader or the luminescence mode of the integrated FLIPRTETRA instrument from Molecular Devices. The latter instrument is also used for fluorescence mode assays, since it permits a wide range of excitation/emission options. We also utilize more specialized fluorescence-based plate readers for particular assays if advantageous. Even if you provide a fully-configured assay, our experienced assay development scientists can offer fine adjustments to increase the quality of your hits.
All screening data are automatically deposited into our custom relational database. Automated real-time data processing allows us to retest those plates that do not meet our strict quality-control parameters for Z', hit distribution and failed wells the same day. Sophisticated data processing methodologies monitor for systematic errors. All putative hits discovered in the initial screen are rapidly cherry-picked retested by multi-well hit confirmation experiments our automated system to confirm and extend the initial finding. Finally the IC/EC50 values for the confirmed hits will be determined. And when it comes to reporting data back to you, you can choose from a variety of options including simple text or Excel tables, database exports, and graphical views using Spotfire® visualizations.
At the end of the screening campaign, we will provide more than just a list of "hits" to our clients. Our emphasis is on high-quality
data. That means attention to every detail during the complete project - careful choices of readout technologies, proper concentrations for reference ligands, effective counter-screens and more.
Please contact us to receive more information on our Compound Collections. |
|
|
|
|
|
|
